Results 171 to 180 of about 49,828 (259)
Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study. [PDF]
Lee JY, Park DG, Sung J.
europepmc +1 more source
Parasitoid wasps deploy maternal and embryonic factors to reprogramme host physiology. Venom, calyx fluid, polydnaviruses, teratocytes and larval secretions act in a coordinated, compartmentalised manner. Host‐regulation factors are promising sources of insecticidal, antimicrobial and bioinspired translational molecules.
Ciro Pedro G. Pinto +2 more
wiley +1 more source
ERRATUM: Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction. [PDF]
Apaijai N +4 more
europepmc +1 more source
This study reveals that monocyte cholesterol accumulation correlates with the severity of diabetic complications and predicts post‐discharge glycemic deterioration. These findings suggest that monocytic cholesterol serves as a novel translational biomarker reflecting ‘metabolic memory’ and therapeutic resistance in patients with type 2 diabetes ...
Hideyuki Okuma +3 more
wiley +1 more source
Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus and Liver Cirrhosis: A Systematic Review and Meta-Analysis. [PDF]
Shetty USA +7 more
europepmc +1 more source
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi +4 more
wiley +1 more source
Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. [PDF]
Aloke C +4 more
europepmc +1 more source
Continuous glucose monitoring (CGM) visualized cyclic glycemic fluctuations associated with the 4‐days‐on/3‐days‐off capivasertib schedule. Compared with off‐treatment days, dosing days showed higher mean sensor glucose, greater coefficient of variation (CV), more time above 250 mg/dL, and lower time in range (TIR; 70–180 mg/dL).
Hiroki Okumura +13 more
wiley +1 more source

